S&P 500   4,605.40 (+0.84%)
DOW   34,656.20 (+0.50%)
QQQ   395.61 (+0.45%)
AAPL   168.90 (+2.18%)
MSFT   335.31 (+1.43%)
FB   317.82 (-2.05%)
GOOGL   2,874.49 (+1.29%)
AMZN   3,503.20 (-0.11%)
TSLA   1,143.87 (-0.08%)
NVDA   323.43 (-1.02%)
BABA   125.04 (-1.95%)
NIO   39.54 (+1.05%)
CGC   10.31 (-3.73%)
AMD   154.38 (-2.52%)
GE   95.18 (+0.20%)
MU   87.40 (+4.05%)
T   22.50 (-1.45%)
F   19.99 (+4.17%)
DIS   144.85 (-0.03%)
PFE   54.56 (+1.54%)
ACB   6.22 (-3.12%)
AMC   32.42 (-4.48%)
BA   193.54 (-2.18%)
S&P 500   4,605.40 (+0.84%)
DOW   34,656.20 (+0.50%)
QQQ   395.61 (+0.45%)
AAPL   168.90 (+2.18%)
MSFT   335.31 (+1.43%)
FB   317.82 (-2.05%)
GOOGL   2,874.49 (+1.29%)
AMZN   3,503.20 (-0.11%)
TSLA   1,143.87 (-0.08%)
NVDA   323.43 (-1.02%)
BABA   125.04 (-1.95%)
NIO   39.54 (+1.05%)
CGC   10.31 (-3.73%)
AMD   154.38 (-2.52%)
GE   95.18 (+0.20%)
MU   87.40 (+4.05%)
T   22.50 (-1.45%)
F   19.99 (+4.17%)
DIS   144.85 (-0.03%)
PFE   54.56 (+1.54%)
ACB   6.22 (-3.12%)
AMC   32.42 (-4.48%)
BA   193.54 (-2.18%)
S&P 500   4,605.40 (+0.84%)
DOW   34,656.20 (+0.50%)
QQQ   395.61 (+0.45%)
AAPL   168.90 (+2.18%)
MSFT   335.31 (+1.43%)
FB   317.82 (-2.05%)
GOOGL   2,874.49 (+1.29%)
AMZN   3,503.20 (-0.11%)
TSLA   1,143.87 (-0.08%)
NVDA   323.43 (-1.02%)
BABA   125.04 (-1.95%)
NIO   39.54 (+1.05%)
CGC   10.31 (-3.73%)
AMD   154.38 (-2.52%)
GE   95.18 (+0.20%)
MU   87.40 (+4.05%)
T   22.50 (-1.45%)
F   19.99 (+4.17%)
DIS   144.85 (-0.03%)
PFE   54.56 (+1.54%)
ACB   6.22 (-3.12%)
AMC   32.42 (-4.48%)
BA   193.54 (-2.18%)
S&P 500   4,605.40 (+0.84%)
DOW   34,656.20 (+0.50%)
QQQ   395.61 (+0.45%)
AAPL   168.90 (+2.18%)
MSFT   335.31 (+1.43%)
FB   317.82 (-2.05%)
GOOGL   2,874.49 (+1.29%)
AMZN   3,503.20 (-0.11%)
TSLA   1,143.87 (-0.08%)
NVDA   323.43 (-1.02%)
BABA   125.04 (-1.95%)
NIO   39.54 (+1.05%)
CGC   10.31 (-3.73%)
AMD   154.38 (-2.52%)
GE   95.18 (+0.20%)
MU   87.40 (+4.05%)
T   22.50 (-1.45%)
F   19.99 (+4.17%)
DIS   144.85 (-0.03%)
PFE   54.56 (+1.54%)
ACB   6.22 (-3.12%)
AMC   32.42 (-4.48%)
BA   193.54 (-2.18%)
NASDAQ:RARE

Ultragenyx Pharmaceutical SEC Filings & 10K Form

$76.50
+1.27 (+1.69%)
(As of 12/1/2021 01:24 PM ET)
Add
Compare
Today's Range
$75.20
▼
$77.21
50-Day Range
$73.71
▼
$101.69
52-Week Range
$72.89
▼
$179.65
Volume
5,124 shs
Average Volume
476,390 shs
Market Capitalization
$5.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.7

Ultragenyx Pharmaceutical (NASDAQ:RARE) SEC Filings

DateFilerForm TypeView
09/09/2021
5:22 PM		Parschauer Karah Herdman (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/02/2021
5:11 PM		Bedrosian Camille L (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/12/2021
4:09 PM		Arcturus Therapeutics Holdings Inc. (Subject)
Ultragenyx Pharmaceutical (Filed by)
Form SC 13D/A
07/08/2021
10:56 AM		Harris Erik (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/30/2021
7:46 AM		Ultragenyx Pharmaceutical (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/28/2021
5:27 PM		Ultragenyx Pharmaceutical (Issuer)
WELCH DANIEL G (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/28/2021
5:26 PM		Aliski William (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/28/2021
5:25 PM		Dunsire Deborah (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/28/2021
5:24 PM		Ekman Lars (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/28/2021
5:24 PM		Fust Matthew K (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/28/2021
5:23 PM		NARACHI MICHAEL (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/28/2021
5:22 PM		SULIMAN SHEHNAAZ (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/25/2021
8:00 AM		Ultragenyx Pharmaceutical (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/23/2021
4:55 PM		Harris Erik (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2021
8:08 PM		Parschauer Karah Herdman (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2021
7:35 AM		Ultragenyx Pharmaceutical (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/19/2021
7:46 AM		Ultragenyx Pharmaceutical (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/14/2021
7:46 AM		Ultragenyx Pharmaceutical (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/10/2021
5:14 PM		Huang Dennis Karl (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/10/2021
5:13 PM		Parschauer Karah Herdman (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/10/2021
5:13 PM		Pinion John Richard (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/10/2021
5:12 PM		Huizenga Theodore Alan (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/10/2021
5:11 PM		Kassberg Thomas Richard (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/10/2021
5:11 PM		KAKKIS EMIL D (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/10/2021
5:10 PM		Harris Erik (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/10/2021
5:09 PM		Bedrosian Camille L (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/07/2021
3:46 PM		Ultragenyx Pharmaceutical (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/07/2021
3:24 PM		Ultragenyx Pharmaceutical (Filer)
Form 424B5
05/05/2021
10:32 AM		KAKKIS EMIL D (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
04/21/2021
7:07 PM		Harris Erik (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
04/19/2021
4:17 PM		Bedrosian Camille L (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
04/19/2021
4:16 PM		Huizenga Theodore Alan (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
04/16/2021
5:03 AM		Ultragenyx Pharmaceutical (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/09/2021
11:37 AM		Huizenga Theodore Alan (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2021
7:55 PM		Kassberg Thomas Richard (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2021
7:48 PM		Pinion John Richard (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2021
7:47 PM		Parschauer Karah Herdman (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2021
7:43 PM		Huizenga Theodore Alan (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2021
7:42 PM		Harris Erik (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2021
7:39 PM		Huang Dennis Karl (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2021
7:38 PM		Dier Mardi (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2021
7:37 PM		Bedrosian Camille L (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2021
7:36 PM		KAKKIS EMIL D (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/23/2021
1:30 PM		Aliski William (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/16/2021
12:24 PM		Capital World Investors (Filed by)
Ultragenyx Pharmaceutical (Subject)
Form SC 13G/A
02/16/2021
12:16 PM		Capital Research Global Investors (Filed by)
Ultragenyx Pharmaceutical (Subject)
Form SC 13G/A
02/12/2021
12:06 PM		FEDERATED HERMES, INC. (Filed by)
FEDERATED HERMES, INC. (Filed by)
Ultragenyx Pharmaceutical (Subject)
Form SC 13G/A
02/03/2021
7:04 PM		Harris Erik (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/03/2021
7:03 PM		KAKKIS EMIL D (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 5
Annual statement of changes in beneficial ownership of securities  
02/03/2021
7:02 PM		Aliski William (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 5
Annual statement of changes in beneficial ownership of securities  
02/03/2021
7:01 PM		Huizenga Theodore Alan (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 5
Annual statement of changes in beneficial ownership of securities  
02/02/2021
3:28 PM		Bedrosian Camille L (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/01/2021
7:30 AM		BlackRock Inc. (Filed by)
Ultragenyx Pharmaceutical (Subject)
Form SC 13G/A
01/21/2021
7:46 AM		Ultragenyx Pharmaceutical (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/19/2021
3:01 PM		Bedrosian Camille L (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/11/2021
6:15 AM		Ultragenyx Pharmaceutical (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/08/2021
6:05 PM		Huizenga Theodore Alan (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2021
8:16 AM		Ultragenyx Pharmaceutical (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/05/2021
5:45 PM		KAKKIS EMIL D (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/17/2020
3:15 PM		Ultragenyx Pharmaceutical (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/10/2020
3:55 PM		Arcturus Therapeutics Holdings Inc. (Issuer)
Ultragenyx Pharmaceutical (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/10/2020
3:51 PM		Arcturus Therapeutics Holdings Inc. (Subject)
Ultragenyx Pharmaceutical (Filed by)
Form SC 13D/A
12/07/2020
5:04 AM		Ultragenyx Pharmaceutical (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/06/2020
3:16 PM		Solid Biosciences Inc. (Subject)
Ultragenyx Pharmaceutical (Filed by)
Form SC 13D
11/04/2020
2:44 PM		KAKKIS EMIL D (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/02/2020
4:05 PM		Parschauer Karah Herdman (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/02/2020
3:05 PM		Ultragenyx Pharmaceutical (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/30/2020
4:28 PM		Parschauer Karah Herdman (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/30/2020
4:26 PM		Solid Biosciences Inc. (Issuer)
Ultragenyx Pharmaceutical (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
10/29/2020
3:02 PM		Ultragenyx Pharmaceutical (Filer)
Form 424B5
10/28/2020
6:52 AM		Ultragenyx Pharmaceutical (Filer)
Form 424B5
10/27/2020
3:20 PM		Ultragenyx Pharmaceutical (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/27/2020
3:07 PM		Ultragenyx Pharmaceutical (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/26/2020
3:11 PM		Ultragenyx Pharmaceutical (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/23/2020
7:16 AM		Ultragenyx Pharmaceutical (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/16/2020
6:23 PM		KAKKIS EMIL D (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2020
6:22 PM		Bedrosian Camille L (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2020
6:21 PM		Parschauer Karah Herdman (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2020
6:20 PM		Kassberg Thomas Richard (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2020
6:20 PM		Harris Erik (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2020
6:19 PM		Pinion John Richard (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2020
6:18 PM		Huang Dennis Karl (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2020
6:16 PM		Huizenga Theodore Alan (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2020
6:15 PM		Sharp Shalini (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/13/2020
4:55 PM		Pinion John Richard (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/13/2020
4:53 PM		Parschauer Karah Herdman (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/13/2020
4:52 PM		Dier Mardi (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/13/2020
4:52 PM		Dier Mardi (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
10/13/2020
5:07 AM		Ultragenyx Pharmaceutical (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/07/2020
1:57 PM		Parschauer Karah Herdman (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/24/2020
3:47 PM		Parschauer Karah Herdman (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/02/2020
3:26 PM		KAKKIS EMIL D (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/02/2020
8:00 AM		Ultragenyx Pharmaceutical (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/25/2020
2:56 PM		Aliski William (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/19/2020
1:12 PM		Parschauer Karah Herdman (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/19/2020
1:11 PM		Sharp Shalini (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/11/2020
11:21 AM		SIEGALL CLAY B (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/31/2020
10:29 AM		Ultragenyx Pharmaceutical (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/15/2020
12:22 PM		KAKKIS EMIL D (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/10/2020
4:21 PM		Huizenga Theodore Alan (Reporting)
Ultragenyx Pharmaceutical (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.